ReviewFrontiers in immunology2026

Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1.

Ziwei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.